1/ Nice thread on the #RECOVERY trial results on #Tocilizumab for hospitalized patients w #Covid_19
@nickmmark additionally touches on the issue of different results from different trials, worth having a look ;-)
My 2 cents: https://twitter.com/nickmmark/status/1359964191306567680
@nickmmark additionally touches on the issue of different results from different trials, worth having a look ;-)
My 2 cents: https://twitter.com/nickmmark/status/1359964191306567680
2/ #RECOVERY authors have included a forest plot w a MA on mortality comparing tocilizumab vs SoC:
Pulling together data from smaller trials, the overall effect points to a similar direction and magnitude of the effect of that seen on RECOVERY
https://bit.ly/3al92Dc
Pulling together data from smaller trials, the overall effect points to a similar direction and magnitude of the effect of that seen on RECOVERY
https://bit.ly/3al92Dc
3/ In the RECOVERY trial, there's no evidence of any effect modification across pre-specified variables, which is reassuring
4/ The pop included in the RECOVERY trial is pretty similar to the pop included in our study (TOCIBRAS), where increase mortality w TOCI was observed:
Similiar age, sex proportion
Similar inflammatory profile (high CRP, ferritin)
Similar disease duration
Only ~ 15% on IMV
But,
Similiar age, sex proportion
Similar inflammatory profile (high CRP, ferritin)
Similar disease duration
Only ~ 15% on IMV
But,
5/ the results were so different :-/
Of course, our study was so much smaller than RECOVERY, and a random high could have occurred. I truly hope that this is the explanation for the discrepancy rather than effect modification
Of course, our study was so much smaller than RECOVERY, and a random high could have occurred. I truly hope that this is the explanation for the discrepancy rather than effect modification
6/ Although not able 2 explain it all (differences), the results seen on RECOVERY (& REMAP-CAP) are reassuring!
Tocilizumab+steroids in Covid19 pts should be the new standard of care for pts with similar baseline characteristics as RECOVERY's
Congrats to authors! @PeterHorby
Tocilizumab+steroids in Covid19 pts should be the new standard of care for pts with similar baseline characteristics as RECOVERY's
Congrats to authors! @PeterHorby